EMG
BRNS

ETF Managers Group’s Barinthus Biotherapeutics BRNS Stock Holding History

ETF Managers Group’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,087
Closed -$108K – 707
2021
Q4 		$108K Sell
10,087
-2,836
-22% -$35.8K ﹤0.01% 633
2021
Q3 		$203K Buy
12,923
+2,810
+28% +$42.7K ﹤0.01% 612
2021
Q2 		$145K Buy
+10,113
New +$150K ﹤0.01% 616

Other funds holding BRNS

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IIM
Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MGIM
M&G Investment Management London, United Kingdom $28.2B AUM 25.87% 1-Year Est. Return

ETF Managers Group's BRNS Position: Q1 2022 in Review

ETF Managers Group sold out of Barinthus Biotherapeutics (BRNS) in Q1 2022, closing a stake of 10,087 shares — an estimated $108K sold.

ETF Managers Group first reported a position in BRNS in Q2 2021 and held it in 3 quarters. The position peaked at $203K in Q3 2021. 12 funds tracked by Wall St. Rank hold BRNS as of Q1 2022.

  • ETF Managers Group reported no remaining Barinthus Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • ETF Managers Group sold 10,087 Barinthus Biotherapeutics shares in Q1 2022, an estimated $108K.
  • ETF Managers Group first reported a position in Barinthus Biotherapeutics in Q2 2021 and held it in 3 quarters.
  • ETF Managers Group's Barinthus Biotherapeutics position peaked at $203K in Q3 2021.
  • 12 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q1 2022.

Based on ETF Managers Group's 13F filing for Q1 2022, filed 13 May 2022.